India pharmaceutical sector is the largest provider of generic drugs globally supplying over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medicine in UK.
India dominates an important position in the global segment with a large pool of scientists and engineers who have the potential to steer the industry ahead. The domestic pharmaceuticals market is the second largest in terms of volume and thirteenth largest in terms of value, having large raw material base advantage.
The growth story has developed by leaps and bounds in the last three decades and is only cultivating further. As reported by top strategy consulting firms, the industry has posted double-digit growth over the last few years, rising from US $20 billion in 2015 to US $36.7 Billion in 2017 and projected to grow to US $55 Billion by 2020.
Initiatives taken by the GOI in past five years have been reassuring:
- The National Health Protection Scheme (2018-19) is largest government funded healthcare programme in the world, expected to benefit 100 million poor families in the country by providing a cover of up to Rs. 5 lakh (US$ 7,723.2) per family per annum
- In October 2018, the Uttar Pradesh Government announced setting up six pharma parks and has received investment commitments of more than Rs. 6,000 crore (US$ 712-855 million) for the same
- The GOI is also planning to set up an electronic platform to regulate online pharmacies under a new policy
- 'Pharma Vision 2020' is aimed at making India a global market leader in end-to-end drug manufacture.
As per market research companies in india, the Indian pharmaceutical Industry (IPI) has grown at nearly 12 to 15 per cent in the past few years, which is a tremendous pace of growth if we compare it to that of the US or European markets. The industry growth is expected to continue in double digits, making India rank amongst top five global pharma markets by 2030.
Big international houses are becoming more active in India as they have both money and resources to flourish. Tecnova Global has successfully executed nearly 100 projects in the pharmaceuticals and healthcare domain with well-known brands such as GlaxoSmithKline, Baxter, Helvoet Pharma, Sanofi-Synthelabo and many more.
India’s strong position as a pharma supplier rests on:
Cost
- The cost of manufacturing formulations in India remains 30‐40 percent lower than other comparative manufacturing hubs such as China and Eastern Europe
Domestic Requirement
- One need to keep in mind that India has been implored by its own people and quite a few developed countries to bring healthcare to the top of its development agenda
International Pharma Companies that have been successfully operating in India
PFIZER
Pfizer Inc., the parent company of Pfizer Limited, was founded in New York in 1849. Today, it is the world’s premiere biopharmaceutical corporation producing medicines, vaccines and other consumer healthcare products across 175 markets. Pfizer Limited is the 3rd largest Multinational Pharmaceutical Company in India with a portfolio of 142 products across 15 therapeutic areas.
NOVARTIS
Novartis India Limited is part of a Swiss multinational pharmaceutical company (Novartis International AG) founded as part of a merger between Ciba-Geigy and Sandoz in 1996. In India, Novartis is primarily engaged in the trading of drugs and pharmaceuticals via the following Pharmaceuticals, Eye Care and Generic Medicines. As on July 2018, the company's core operating profit rose 7% to $3.541 billion and Sales climbed 5% to $13.158 billion as per Reuters poll.
ROCHE
In November 1957, F. Hoffmann-La Roche Ltd. (FHLR), Basle, finalised negotiations with the GOI for the local manufacture of synthetic Vitamin A and pharmaceutical specialties. After launch of two innovative cancer drugs, the company feels that, under its ‘Vision 2030’, the “right collaboration and right focus” along with sustainable and innovative solutions will accelerate healthcare.
Pharmaceutical consulting companies often mention Piramal Enterprises Limited (PEL) growth trajectory as a classic example of opportunism meeting expertise. From Rs. 15,000 crore it received from Abbott, Rs. 6,000 crore was invested in the pharma segment. The business has now grown to earn revenues of Rs. 4,000 crore.
Comments
Post a Comment